ClinicalTrials.gg
TerminatedNCT06736262Updated Aug 6, 2026

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

A Phase 2 interventional study of Briquilimab in Urticaria Chronic, sponsored by Jasper Therapeutics, Inc.. Terminated at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Jasper Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Enrollment
39th of 58
67 · median 132
Started
2024
with 3 others
Phase 2
23 of 64
4 open now
Registered
50th of 64
by date
Lead sponsor
2 of 64
Jasper Therapeutics, Inc.

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 39th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2024, is one of 23 in phase 2, and was the 50th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.

Read the detailed description

This is a Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial, specifically the BEACON (JSP-CP-011) and SPOTLIGHT (JSP CP-010) trials (referred to as "parent studies") and future CU trials sponsored by Jasper Therapeutics.

03

Conditions studied

  • Urticaria Chronic

Keywords

  • Itch
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provides informed written consent.
  2. Previously participated in and completed an eligible Jasper-sponsored clinical trial (in the last 4 months) without any product (IP)-related anaphylactic event
  3. Disease specific eligibility:

    1. Participants with CSU have a UAS7 of 16 or greater following the completion of at least 8 weeks of safety follow up in the parent study OR anyone who completed their parent study regardless of UAS7 score.
    2. Participants with CIndU (cold contact urticaria [ColdU] or symptomatic dermographism) have a UCT of 12 or less following the completion of at least 8 weeks of safety follow up in the parent study OR anyone who completed their parent study regardless of UCT score.
  4. The laboratory parameters to be within the acceptable range as follows:

    1. : ≥ 10 g/dL
    2. : ≥ 100,000/mm3
    3. Neutrophils: ≥ 1,500/mm3
    4. (ALT) or aspartate aminotransferase (AST) \< 3 × the (ULN)
    5. Serum total \< 2 × ULN, unless attributable to Gilbert's syndrome
    6. Estimated (eCrCl) by the Cockcroft-Gault equation (using total body weight) ≥ 30 mL/min
  5. Participants willing to abstain from blood donations while being on the trial (Screening to end of trial [EOT]).
  6. Male participants (who are not vasectomized) who are heterosexually active must use highly effective methods and must abstain from sperm donation during the trial and for at least 8 months after the last dose of briquilimab. A male participant is considered vasectomized if he had a vasectomy at least 4 months prior to Screening and if he has received post-surgical medical assessment of the surgical success of the vasectomy
  7. Female participants of who are heterosexually active (defined in Section 5.2.1.1) must use highly effective contraceptive methods (Section 5.2.1) during the trial and for at least 90 days after the last dose of briquilimab. Female participants of non-childbearing potential must be surgically sterile (i.e., had undergone complete hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or be in a menopausal state (at least 1 year without menses).

Exclusion criteria

Exclusion Criteria:

  1. Participated in or currently participating in an interventional clinical trial investigating an experimental therapy following cessation of participation in a Jasper-sponsored CU trial.
  2. Other active diseases with possible symptoms of urticaria, wheals or angioedema, including urticarial vasculitis, erythema multiforme, systemic or cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)
  3. Women who are pregnant or nursing or intend to become pregnant during the course of the trial
  4. Any known or to any component of briquilimab, drugs of similar chemical classes (i.e., to murine, chimeric or human antibodies) or antihistamines or leukotrienes. Those who have previously experienced an IP-related anaphylactic event, IP-related SAE, or IP-related AE that led to treatment discontinuation in a prior Jasper-sponsored urticaria clinical trial, which in the opinion of the Investigator or medical monitor, may indicate that continued treatment could present an unreasonable risk to the participant are also excluded.
  5. Any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or briquilimab administration or could interfere with the interpretation of trial results and, in the judgment of the Investigator, would make the participant inappropriate for entry into the trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Briquilimab

    Briquilimab via SQ injection

    Drug: Briquilimab

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of briquilimab

    Incidence and severity of AEs including SAEs, TEAEs and AEIs.

    Time frame: From signing the informed consent form through study completion (an average of one year)

07

Study locations

19 sites
  • Investigative Site 118
    Birmingham, Alabama 35244, United States
  • Investigative Site 108
    Little Rock, Arkansas 72205, United States
  • Investigative Site 105
    San Diego, California 92123, United States
  • Investigative Site 116
    Tampa, Florida 33613, United States
  • Investigative Site 109
    Boise, Idaho 83706, United States
  • Investigative Site 124
    Normal, Illinois 61761, United States
  • Investigative Site 110
    Indianapolis, Indiana 46250, United States
  • Investigative Site 123
    Lafayette, Louisiana 70508, United States
  • Investigative Site 101
    Baltimore, Maryland 21224, United States
  • Investigative Site 121
    White Marsh, Maryland 21162, United States
  • Investigative Site 103
    Cincinnati, Ohio 45236, United States
  • Investigative Site 111
    Murray, Utah 84107, United States
  • Investigative Site 115
    Seattle, Washington 98101, United States
  • Investigative Site 210
    München, Bavaria 80802, Germany
  • Investigative Site 202
    Marburg, Hesse 35043, Germany
  • Investigative Site 204
    Münster, North Rhine-Westphalia 48149, Germany
  • Investigative Site 209
    Dresden, Saxony 01307, Germany
  • Investigative Site 206
    Lübeck, Schleswig-Holstein 23538, Germany
  • Investigative Site 201
    Berlin, 12203, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Jul 2026, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Dec 16, 2024
StartActual
Nov 26, 2024
Primary completionActual
Jul 21, 2026
CompletionActual
Jul 21, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06736262
Lead sponsor
Jasper Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Nov 26, 2024
Primary completion
Jul 21, 2026
Completion
Jul 21, 2026
Last update
Aug 6, 2026

Study contacts

Medical Director
study director · Jasper Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Briquilimab

Start the discussion